ST Elevation Acute Myocardial Infarction Clinical Trial
Official title:
Does Cyclosporine ImpRove Clinical oUtcome in ST Elevation Myocardial Infarction Patients
Infarct size is a major determinant of prognosis after Acute Myocardial Infarction (AMI). The investigators recently reported that cyclosporine A, when administered immediately prior to percutaneous coronary intervention (PCI), can significantly reduce infarct size in STEMI (ST Elevation acute Myocardial Infarction) patients. The objective of the present study is to determine whether cyclosporine can improve STEMI patient clinical outcome. Nine-hundred and seventy two patients with ST elevation MI will be entered into a multicentre, randomized, placebo-controlled, double-blinded study. They will receive one single injection of cyclosporine A (CicloMulsion, verum) or an equivalent volume of placebo prior to reperfusion therapy by PCI. The incidence of the combined endpoint (mortality, hospitalization for heart failure, left ventricular (LV) remodeling) will be assessed at one year and three years after treatment.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02151929 -
Bioresorbable Vascular Scaffold in Patients With Myocardial Infarction
|
Phase 4 | |
| Completed |
NCT02404376 -
COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial
|
Phase 3 | |
| Completed |
NCT02934217 -
Does Cyclosporine ImpRove Clinical oUtcome in ST Elevation Myocardial Infarction Patients at 3 Years of Follow-up. CIRCUS II Study
|
Phase 3 | |
| Terminated |
NCT00650975 -
ThromboAblation in Acute Myocardial Infarction
|
Phase 2/Phase 3 | |
| Unknown status |
NCT01420614 -
RadIal Versus Femoral InvEstigation in ST Elevation Acute Coronary Syndrome
|
N/A |